Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 26, 2022

Quételet (Body Mass) Index and Dapagliflozin in CKD

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD
Diabetes Obes Metab 2022 Jan 04;[EPub Ahead of Print], GM Chertow, P Vart, N Jongs, AM Langkilde, JJV McMurray, R Correa-Rotter, P Rossing, CD Sjöström, BV Stefansson, RD Toto, DC Wheeler, HJL Heerspink

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading